Common TitlePOLARIS-2
Official Title Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials
Phase Phase III
ClinicalTrials.gov NCT02607800
Treatments
Sofosbuvir-Velpatasvir
, Sofosbuvir-Velpatasvir
Tradename:EpclusaOther Names:SOF-VELClass:FDA-ApprovedSofosbuvir-Velpatasvir-Voxilaprevir
Sofosbuvir-Velpatasvir-Voxilaprevir
Tradename:VoseviOther Names:SOF-VEL-VOXClass:FDA-ApprovedFunding
IndustryGilead Sciences